These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 21155390)

  • 1. Biodegradable microfibers deliver the antitumor drug temozolomide to glioma C6 cells in vitro.
    Fan X; Ni S; Qi H; Wang X; Wang C; Liu Y
    Pharmazie; 2010 Nov; 65(11):830-4. PubMed ID: 21155390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
    Zhang H; Gao S
    Int J Pharm; 2007 Feb; 329(1-2):122-8. PubMed ID: 17000068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodegradable implants efficiently deliver combination of paclitaxel and temozolomide to glioma C6 cancer cells in vitro.
    Ni S; Fan X; Wang J; Qi H; Li X
    Ann Biomed Eng; 2014 Jan; 42(1):214-21. PubMed ID: 24018608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodegradable microparticles and fiber fabrics for sustained delivery of cisplatin to treat C6 glioma in vitro.
    Xie J; Tan RS; Wang CH
    J Biomed Mater Res A; 2008 Jun; 85(4):897-908. PubMed ID: 17896769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells.
    Xu X; Chen X; Xu X; Lu T; Wang X; Yang L; Jing X
    J Control Release; 2006 Sep; 114(3):307-16. PubMed ID: 16891029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microparticles developed by electrohydrodynamic atomization for the local delivery of anticancer drug to treat C6 glioma in vitro.
    Xie J; Marijnissen JC; Wang CH
    Biomaterials; 2006 Jun; 27(17):3321-32. PubMed ID: 16490248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide and treatment of malignant glioma.
    Friedman HS; Kerby T; Calvert H
    Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide in malignant gliomas: current use and future targets.
    Villano JL; Seery TE; Bressler LR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
    Ma J; Li S; Reed K; Guo P; Gallo JM
    J Pharmacol Exp Ther; 2003 Jun; 305(3):833-9. PubMed ID: 12626639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
    Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
    Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma.
    Ranganath SH; Wang CH
    Biomaterials; 2008 Jul; 29(20):2996-3003. PubMed ID: 18423584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Orthogonal experiments for optimizing the formulation and preparation conditions of temozolomide solid lipid nanoparticles].
    Dou M; Huang G; Xi Y; Zhang N
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Oct; 25(5):1141-5. PubMed ID: 19024463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
    Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is protracted low-dose temozolomide feasible in glioma patients?
    Tosoni A; Cavallo G; Ermani M; Scopece L; Franceschi E; Ghimenton C; Gardiman M; Pasetto L; Blatt V; Brandes AA
    Neurology; 2006 Feb; 66(3):427-9. PubMed ID: 16476947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glioma therapy up-date].
    de la Fuente BP; Dalmau J; Rosenfeld M
    Neurologia; 2007 Apr; 22(3):159-69. PubMed ID: 17364254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
    Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
    Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
    Heimberger AB; Archer GE; McLendon RE; Hulette C; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2000 Oct; 6(10):4148-53. PubMed ID: 11051269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic activation of temozolomide measured in vivo using positron emission tomography.
    Saleem A; Brown GD; Brady F; Aboagye EO; Osman S; Luthra SK; Ranicar AS; Brock CS; Stevens MF; Newlands E; Jones T; Price P
    Cancer Res; 2003 May; 63(10):2409-15. PubMed ID: 12750260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
    Zhang YH; Yue ZJ; Zhang H; Tang GS; Wang Y; Liu JM
    Eur J Pharm Biopharm; 2010 Nov; 76(3):371-5. PubMed ID: 20816959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.